Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Justin Kopit, Lisa Licitra, Mark Lynch, Joël Guigay, A. Dimitrios Colevas, Jérôme Fayette, Tamara Rordorf, Makoto Tahara, Nabil F. Saba, Lara Carmen Iglesias Docampo, Kevin J. Harrington, Maura L. Gillison, Robert I. Haddad, Stefan Kasper, Naomi Kiyota, Francis P. Worden, George R. Blumenschein, Robert L. Ferris, Caroline Even, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 35:6019-6019
6019 Background: In CheckMate 141, a randomized, phase 3 trial, nivo demonstrated superior overall survival (OS) and better tolerability in patients (pts) with PR R/M SCCHN compared with IC. Pts with SCCHN progressing within 6 mos of platinum in the
Autor:
Lorna Grove, James Spicer, Sally Ellis, Sola Adeleke, Martin Forster, Jennifer Laude, Simon Smith, Glen Clack, Z. Viney, Kevin J. Harrington, Lyndall McLellan, George Lazaridis, Magnus T. Dillon
Publikováno v:
Journal of Clinical Oncology. 34:TPS2603-TPS2603
Tumour control rates from radiation therapy (RT) are limited by normal tissue toxicities. Novel strategies are required to selectively sensitize tumour cells to radiation-induced DNA damage. The G2 cell cycle checkpoint is an attractive target for th
Autor:
Petra Holečková, Georgy M. Manikhas, Iman El-Hariry, Natalie Franklin, Sergio Santillana, Hisham Mehanna, Paul Wissel, Minish Mahendra Jain, Geza Horvai, Stéphane Temam, Thelma Netherway, Jean Bourhis, Nigel Biswas-Baldwin, Ida D'Onofrio, Yan Sun, Stefan Dietzsch, Pavol Dubinsky, Philippe Legenne, Kevin J. Harrington, Anil K. D'Cruz
Publikováno v:
ResearcherID
6005 Background: Epidermal growth factor receptor (EGFR) and ErbB2 are overexpressed in up to 90% and 40% of SCCHN, respectively. L, a tyrosine kinase inhibitor (TKI) of both EGFR and ErbB2, demonstrates tumor responses in SCCHN. Methods: Patients wi